Healthcare / BiotechnologyNasdaqGS
$5.58
+0.16 (+2.95%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-121.3M · quality 69.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
27/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$914M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-97.7%
↓Gross Margin
N/A
•Debt/Equity
0.12
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2019–2025 · 6 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.90x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-206.7M · FCF $-186.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Net Income | $-206.7M | $-206.7M | $-138.2M | $-134.2M | $-141.9M | $-130.3M | $-63.4M | $-37.2M |
| EBITDA | $-213.8M | $-213.8M | $-151.5M | $-141.6M | $-143.4M | $-128.6M | $-62.8M | $-32.0M |
| EPS | — | — | -1.01 | -1.77 | -2.60 | -3.40 | — | — |
| Balance Sheet | ||||||||
| Debt/Equity | 0.12 | 0.12 | 0.10 | 0.13 | 0.14 | — | — | — |
| Current Ratio | 6.35 | 6.35 | — | — | — | — | — | — |
| Cash Flow | ||||||||
| Free Cash Flow | $-186.5M | $-186.5M | $-118.0M | $-121.3M | $-122.8M | $-107.8M | $-53.6M | $-28.6M |
| Returns | ||||||||
| ROE | -97.7% | -97.7% | -47.2% | -53.6% | -61.4% | -56.2% | -18.4% | 37.0% |
| Valuation | ||||||||
| P/B | 3.94 | 3.94 | 2.54 | 1.40 | 1.13 | — | — | — |
| Growth & Yield | ||||||||
| EPS Growth | — | — | 42.9% | 31.9% | — | — | — | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+173.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.01 → n/d
Residual
+173.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.